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Background: Intracellular Ca2þ([Ca2þ]i) is a platelet aggregation-inducing molecule. Therefore, under-
standing the inhibitory mechanism of [Ca2þ]i mobilization is very important to evaluate the antiplatelet
effect of a substance. This study was carried out to understand the Ca2þ-antagonistic effect of total
saponin from Korean Red Ginseng (KRG-TS).
Methods: We investigated the Ca2þ-antagonistic effect of KRG-TS on cyclic nucleotides-associated phos-
phorylation of inositol 1,4,5-trisphosphate receptor type I (IP3RI) and cyclic adenosine monophosphate
(cAMP)-dependent protein kinase (PKA) in thrombin (0.05 U/mL)-stimulated human platelet aggregation.
Results: The inhibition of [Ca2þ]i mobilization by KRG-TS was increased by a PKA inhibitor (Rp-8-Br-
cAMPS), which was more stronger than the inhibition by a cyclic guanosine monophosphate (cGMP)-
dependent protein kinase (PKG) inhibitor (Rp-8-Br-cGMPS). In addition, Rp-8-Br-cAMPS inhibited
phosphorylation of PKA catalytic subunit (PKAc) (Thr197) by KRG-TS. The phosphorylation of IP3RI
(Ser1756) by KRG-TS was very strongly inhibited by Rp-8-Br-cAMPS compared with that by Rp-8-Br-
cGMPS. These results suggest that the inhibitory effect of [Ca2þ]i mobilization by KRG-TS is more strongly
dependent on a cAMP/PKA pathway than a cGMP/PKG pathway. KRG-TS also inhibited the release of
adenosine triphosphate and serotonin. In addition, only G-Rg3 of protopanaxadiol in KRG-TS inhibited
thrombin-induced platelet aggregation.
Conclusion: These results strongly indicate that KRG-TS is a potent beneﬁcial compound that inhibits
[Ca2þ]i mobilization in thrombineplatelet interactions, which may result in the prevention of platelet
aggregation-mediated thrombotic disease.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Platelet aggregation is absolutely essential for the formation of a
hemostatic plug when normal blood vessels are injured. However,
the interactions between platelets and thrombin can also causeLaboratory Science, College of Bio
ht  2015, The Korean Society of G
c-nd/4.0/).circulatory disorders, such as thrombosis, atherosclerosis, and
myocardial infarction [1]. Accordingly, inhibition of the platelete
thrombin interaction might be a promising approach for the pre-
vention of thrombosis. It is well-known that thrombin, a platelet
agonist, stimulates platelet aggregation by binding to the Gq-medical Science and Engineering, Inje University, Number 197, Inje-ro, Gimhae-si,
inseng, Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
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vating phospholipase C-b (PLC-b). The activated PLC-b hydrolyzes
phosphatidylinositol 4,5-bisphosphate to inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DG) [2e5]. Moreover, IP3
mobilizes cytosol-free Ca2þ ([Ca2þ]i) from the dense tubular system
by binding to the IP3 receptor type I (IP3RI). The increased [Ca2þ]i
activates both Ca2þ/calmodulin-dependent phosphorylation of
myosin light chain (20 kDa) and DG-dependent phosphorylation of
pleckstrin (47 kDa) to induce granule secretion [adenosine
triphosphate (ATP) secretion] and platelet aggregation [6,7].The
Ca2þ-antagonistic effects of cyclic adenosine monophosphate
(cAMP) and cyclic guanosine monophosphate (cGMP) are mediated
through cAMP- and cGMP-dependent protein kinases (PKA and
PKG, respectively), which phosphorylate the substrate protein
IP3RI. The phosphorylation of IP3RI involves in inhibition of [Ca2þ]i
mobilization [8e10]. Therefore, understanding the mechanism of
IP3RI phosphorylation is very useful for evaluating the Ca2þ-
antagonistic effect of various substances.
Ginseng, the root of Panax ginseng C.A. Meyer, has been used
frequently in traditional Oriental medicine, and is known to possess
various pharmacological effects such as anti-inﬂammatory, anti-
oxidation, antitumor, antidiabetes, and antihepatotoxicity [11,12].
Recently, it has been reported that Korean Red Ginseng (KRG) also
has an effect on cardiovascular disease, which is characterized by
reduction in blood pressure and arterial stiffness by inhibition of
Rho kinase activity [13], anticoagulation by prolonging prothrom-
bin and activated partial thromboplastin times [14], endothelium
relaxation by the nitric oxideecGMP pathway [15], and inhibition
of hypercholesterolemia-induced platelet aggregation [16]. In a
previous report, it has been demonstrated that total saponin from
KRG (KRG-TS) inhibits the production of thromboxane A2 (TXA2) in
platelet-mediated thrombotic disease by suppressing the activities
of cyclooxygenase-1 (COX-1) and thromboxane A2 synthase (TXAS)
[17]. In addition, KRG-TS was reported to be involved in increasing
the cAMP level and subsequent reduction of [Ca2þ]i mobilization in
thrombin-induced rat platelet aggregation [18]. With regard to the
effects of ginsenosides on platelet aggregation, it is well-known
that ginsenoside Rg3 (G-Rg3) and its chemical derivatives (dihy-
droxyginsenoside Rg3 and ginsenoside Rp1) exhibit antiplatelet
effects by regulating the aggregation-inhibiting molecule (cAMP)
and aggregation-stimulating molecules (extracellular kinase 2,
tyrosine kinase-dependent phosphoproteins, TXA2, intracellular
Ca2þ, integrin aIIb/b3, etc.) [19e21]. In this study, to understand the
inhibition of [Ca2þ]i mobilization by KRG-TS [18], we investigated
whether KRG-TS is involved in phosphorylation of IP3RI. We also
examined which cyclic nucleotide of cAMP and cGMP participates
in IP3RI phosphorylation to attenuate [Ca2þ]i mobilization in
thrombin-induced human platelet aggregation. In addition, our
results showed that only G-Rg3 of protopanaxadiol in KRG-TS
inhibited thrombin-induced platelet aggregation.
2. Materials and methods
2.1. Materials
KRG-TS was obtained from Korea Ginseng Corporation R&D
Headquarters (Daejeon, Korea). Thrombin was purchased from
Chrono-logCorporation (Havertown, PA,USA). TheATPassaykitwas
purchased from Biomedical Research Service Center (Buffalo, NY,
USA). Serotonin enzyme-linked immunosorbent assay (ELISA) kit
waspurchased fromLaborDiagnostikaNordGmbH&Co. (Nordhorn,
Germany). Fura 2-acetoxymethyl (Fura 2-AM) and other reagents
were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Anti-
phospho-IP3RI (Ser1756), antiphospho-PKA catalytic subunit (PKAc;
Thr197), antirabbit immunoglobulinG (IgG)ehorseradishperoxidaseconjugate (HRP), and lysis buffer were obtained from Cell Signaling
(Beverly, MA, USA). Polyvinylidene diﬂuoride (PVDF) membrane
was obtained from GE Healthcare (Piscataway, NJ, USA). Enhanced
chemiluminescence (ECL) solution was purchased from GE Health-
care (Chalfont St, Giles, Buckinghamshire, UK). Protopanaxadiol
saponins [PPDSs; G-Ra1, G-Rb1, G-Rb2, G-Rb3, G-Rc, G-Rd, G-Rg3
(20R), G-Rg3 (20S), andG-Rh2 (20R)] andprotopanaxatriol saponins
[PPTSs; G-Re, G-Rf, G-Rg1, G-Rg2 (20R), and G-Rh1 (20S)] were
purchased from Ambo Institute (Daejeon, Korea).
2.2. Preparation of washed human platelets
Human-platelet-rich plasma (PRP) anticoagulated with acide
citrateedextrose solution (0.8% citric acid, 2.2% sodium citrate, and
2.45% glucose) was obtained from Korean Red Cross Blood Center
(Changwon, Korea). The PRP was centrifuged for 10 min at 125g to
remove little red blood cells, and was centrifuged for another
10 min at 1,300g to obtain the platelets. The platelets were washed
two times with washing buffer (138mM NaCl, 2.7mM KCl, 12mM
NaHCO3, 0.36mM NaH2PO4, 5.5mM glucose, and 1mM EDTA; pH
6.5). The washed platelets were then resuspended in suspension
buffer (138mM NaCl, 2.7mM KCl, 12mM NaHCO3, 0.36mM
NaH2PO4, 0.49mM MgCl2, 5.5mM glucose, and 0.25% gelatin; pH
6.9) to make up a ﬁnal concentration of 5  108/mL. All of the
aforementioned procedures were carried out at 25C to avoid
platelet aggregation at low temperatures. The Korea National
Institute for Bioethics Policy Public Institutional Review Board
(Seoul, Korea) approved these experiments (PIRB12-072).
2.3. Measurement of platelet aggregation
Washed platelet (108/mL) were preincubated for 3 min at 37C
in the presence of 2mM exogenous CaCl2 with or without (KRG-TS,
A-kinase/G-kinase inhibitor), and then stimulated with thrombin
(0.05 U/mL) for 5 min. Aggregation was monitored using an
aggregometer (Chrono-log Corporation) at a constant stirring
speed of 1,000 rpm. Each aggregation rate was evaluated as an
increase in light transmission. The suspension buffer was used as
the reference (transmission 0). KRG-TS was dissolved in the platelet
suspension buffer (pH 6.9).
2.4. Determination of cytosolic-free Ca2þ
PRP was incubated with 5mM Fura 2-AM at 37C for 60 min.
Because Fura 2-AM is light sensitive, the tube containing the PRP
was covered with aluminum foil during loading. The Fura 2-loaded
washed platelets were prepared using the aforementioned proce-
dure and 108 platelets/mLwere preincubated for 3min at 37Cwith
or without KRG-TS in the presence of 2mM CaCl2, and then stim-
ulatedwith thrombin (0.05 U/mL) for 5min to evaluate [Ca2þ]i. Fura
2 ﬂuorescence was measured using a spectroﬂuorometer (SFM 25;
BioTek Instruments, Milan, Italy) with an excitation wavelength
that was changed every 0.5 s from 340 nm to 380 nm. The emission
wavelength was set at 510 nm. The [Ca2þ]i values were calculated
using the method suggested by Schaeffer and Blaustein [22].
2.5. Determination of ATP and serotonin release
The washed platelets (108/mL) were preincubated for 3 min at
37C with or without (KRG-TS, A-kinase/G-kinase inhibitor, A-ki-
nase/G-kinase activator) in the presence of 2mM CaCl2, and then
stimulated with thrombin (0.05 U/mL). The reaction was termi-
nated and the mixture was centrifused with 200xg at 4C for 10
min. The supernatants were used for the ATP and serotonin release
assays. ATP release was measured in a luminometer (GloMax 20/
Fig. 1. Effects of total saponin from Korean Red Ginseng (KRG-TS) on thrombin-induced human platelet aggregation. (A) Concentration threshold of thrombin on human platelet aggregation. (B) Effects of KRG-TS on resting human
platelets. (C) Effects of KRG-TS on thrombin-induced human platelet aggregation. (D) Half-maximal inhibitory concentration (IC50) value of KRG-TS in thrombin-stimulated human platelet aggregation. Measurement of platelet ag-
gregation was carried out as described in the “Materials and methods” section. The rate of inhibition by KRG-TS was recorded as the percentage of thrombin-induced aggregation rate. The IC50 value of KRG-TS was calculated according
to the four-parameter log-ﬁt method. Data are expressed as the mean  standard deviation (n ¼ 4). *p < 0.05 versus the thrombin-induced human platelet aggregation.
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J.-H. Shin et al / Inhibition of [Ca2+]i mobilization 35720; Promega, Madison, WI, USA) using an ATP assay kit. Serotonin
release was measured with a Synergy HT Multi-Mode Microplate
Reader (BioTek Instruments, Winooski, VT, USA) using a serotonin
ELISA kit.2.6. Western blot analysis for evaluation of PKA catalytic subunit
and IP3RI phosphorylation
Washed platelets (108/mL) were preincubated with or without
KRG-TS in the presence of 2mMCaCl2 for 3min and then stimulated
with thrombin (0.05 U/mL) for 5 min at 37C. The reactions were
terminated by adding an equal volume (250 mL) of lysis buffer
(20mM TriseHCl, 150mM NaCl, 1mM Na2EDTA, 1mM ethylene
glycol tetraacetic acid, 1% Triton X-100, 2.5mM sodium pyrophos-
phate, 1mM serine/threonine phosphatase inhibitor b-glycer-
ophosphate, 1mM ATPase, alkaline and acid phosphatase, protein
phosphotyrosine phosphatase inhibitor Na3VO4,1 mg/mL serine and
cysteine protease inhibitor leupeptin, and 1mM serine protease and
acetylcholinesterase inhibitor phenylmethanesulfonyl ﬂuoride; pH
7.5). Platelet lysates containing the same protein (15 mg) were used
for analysis. Protein concentrations were measured using a bicin-
choninic acid protein assay kit (Pierce Biotechnology, Waltham,
MA, USA). The effects of various substances on PKA catalytic sub-
unit (PKAc) and IP3RI phosphorylation were analyzed by Western
blotting. A 6e8% sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis was used for electrophoresis and a PVDF membrane
was used for protein transfer from the gel. The dilutions for anti-
phospho-IP3RI (Ser1756), antiphospho-PKAc (Thr197), and antirabbit
IgGeHRP were 1:1,000, 1:1,000, and 1:10,000, respectively. The
membranes were visualized using ECL. Blots were analyzed using
the Quantity One version 4.5 software (BioRad, Hercules, CA, USA).Fig. 2. Effects of total saponin from Korean Red Ginseng (KRG-TS) on thrombin-induced hum
protein kinase (PKA) or cyclic guanosine monophosphate-dependent protein kinase (PKG) in
transmission: (a) thrombin (0.05 U/mL); (b) thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL) þ
cGMPS (250mM); and (d) thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL). (B) Effects of KRG-
Washed human platelets (108/mL) were preincubated with KRG-TS (150 mg/mL) in the pres
37C, and then thrombin (0.05 U/mL) was added. Data are expressed as the mean  stan
**p < 0.05 versus the thrombin-stimulated platelets in the presence of KRG-TS (150 mg/mL2.7. Statistical analyses
The experimental results were expressed as the
mean  standard deviation accompanied by the number of obser-
vations. Data were assessed by analysis of variance. If this analysis
indicated signiﬁcant differences among the groupmeans, then each
group was compared by the NewmaneKeuls method. Statistical
analysis was performed using SPSS 21.0.0 (SPSS Inc., Chicago, IL,
USA). A p value < 0.05 was taken to be signiﬁcant.
3. Results
3.1. Effects of KRG-TS on thrombin-induced human platelet
aggregation
The concentration of thrombin-induced maximal human
platelet aggregation was approximately 0.05 U/mL (Fig. 1A).
Therefore, 0.05 U/mL thrombin was used as the human platelet
agonist in this study. The light transmission in response to various
concentrations of KRG-TS in intact platelets was 1.3  0.6% (at
25 mg/mL of KRG-TS), 1.3  0.6% (at 50 mg/mL of KRG-TS), 1.3  0.6%
(at 100 mg/mL of KRG-TS), and 1.3  0.6% (at 150 mg/mL of KRG-TS),
which was not signiﬁcantly different from that observed in resting
platelets [1.0  0.0%; Fig. 1B(aee)]. This result indicated that KRG-
TS alone did not have an effect on platelet aggregation. When
washed human platelets (108/mL) were activated with thrombin,
the aggregation rate was increased up to 87.8  5.7%. However,
various concentrations of KRG-TS (25e150 mg/mL) signiﬁcantly
reduced thrombin-stimulated platelet aggregation in a dose-
dependent manner (Fig. 1C), and its half-maximal inhibitory con-
centration (IC50) was approximately 45 mg/mL (Fig. 1D). This IC50 is
low comparedwith that (81 mg/ml) by rat platelets [18]. In addition,an platelet aggregation in the presence of cyclic adenosine monophosphate-dependent
hibitor. (A) Effects of KRG-TS, PKA inhibitor, or PKG inhibitor on thrombin-elevated light
Rp-8-Br-cAMPS (250mM); (c) thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL) þ Rp-8-Br-
TS, PKA inhibitor, or PKG inhibitor on thrombin-induced human platelet aggregation.
ence of PKA inhibitor (Rp-8-Br-cAMPS) or PKG inhibitor (Rp-8-Br-cGMPS) for 3 min at
dard deviation (n ¼ 4). *p < 0.05 versus the thrombin-stimulated human platelets.
).
Fig. 3. Effects of total saponin from Korean Red Ginseng (KRG-TS) on thrombin-induced [Ca2þ]i mobilization. (A) Inhibitory effects of KRG-TS on thrombin-induced [Ca2þ]i mobilization. (B) Effects of KRG-TS on [Ca2þ]i mobilization in
the presence of cyclic adenosine monophosphate-dependent protein kinase inhibitor (Rp-8-Br-cAMPS). (C) Effects of KRG-TS on [Ca2þ]i mobilization in the presence of cyclic guanosine monophosphate-dependent protein kinase
inhibitor (Rp-8-Br-cGMPS). [Ca2þ]i was determined as described in the “Materials and methods” section. Data are expressed as the mean  standard deviation (n ¼ 4). *p < 0.05 versus the thrombin-stimulated human platelets.
**p < 0.05 versus the thrombin-stimulated human platelets in the presence of KRG-TS (150 mg/mL). ***p < 0.05 versus the thrombin-stimulated human platelets in the presence of KRG-TS (150 mg/mL).
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Table 1
Effects of Rp-8-Br-cAMPS and Rp-8-Br-cGMPS on [Ca2þ]i mobilization
[Ca2þ]i (nM) Increase (%)
KRG-TS (150 mg/mL) þ thrombin (0.05 U/mL) 110.9  1.9 e
KRG-TS (150 mg/mL) þ Rp-8-Br-cAMPS
(250mM) þ thrombin (0.05 U/mL)
238.6  5.9 155.11)
KRG-TS (150 mg/mL) þ Rp-8-Br-cGMPS
(250mM) þ thrombin (0.05 U/mL)
143.6  2.8 29.42)
Data are from Figs. 3B and 3C
KRG-TS, total saponin from Korean Red Ginseng
1) Increase (%) ¼ [(KRG-TS þ thrombin þ Rp-8-Br-cAMPS)  (KRG-
TS þ thrombin)]/(KRG-TS þ thrombin)  100
2) Increase (%) ¼ [(KRG-TS þ thrombin þ Rp-8-Br-cGMPS)  (KRG-
TS þ thrombin)]/(KRG-TS þ thrombin)  100
J.-H. Shin et al / Inhibition of [Ca2+]i mobilization 359150 mg/mL of KRG-TS inhibited up to 95.9% of thrombin-induced
human platelet aggregation (87.8  5.7%).3.2. Effects of KRG-TS on thrombin-induced human platelet
aggregation in the presence of PKA or PKG inhibitor
Because [Ca2þ]i is essential for platelet aggregation, we inves-
tigated the effect of KRG-TS on thrombin-induced platelet aggre-
gation in the presence of PKA or PKG inhibitor, both of which are
intracellular Ca2þ-antagonistic compounds. As shown in Fig. 2A,
thrombin increased light transmission [Fig. 2A(a)], whereas KRG-TS
decreased thrombin-induced light transmission [Fig. 2A(d)]. TheFig. 4. Effect of total saponin from Korean Red Ginseng (KRG-TS) on cyclic adenosine mono
intact platelets (base); Lane 2, thrombin (0.05 U/mL); Lane 3, thrombin (0.05 U/mL) þ KRG-
(0.05 U/mL) þ KRG-TS (150 mg/mL); Lane 6, thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL) þ
cyclic adenosine monophosphate (pCPT-cAMP; 1mM). Western blotting was performed
mean  standard deviation (n ¼ 4). *p < 0.05 versus the thrombin-stimulated human platele
TS (150 mg/mL).PKA inhibitor Rp-8-Br-cAMPS [Figs. 2A(b) and 2B] and the PKG
inhibitor Rp-8-Br-cGMPS [Figs. 2A(c) and 2B] increased KRG-TS-
attenuated light transmission in thrombin-activated platelets. The
inhibitory degree [Figs. 2A(b) and 2B] achieved by the PKA inhibitor
was more stronger than that achieved by the PKG inhibitor
[Figs. 2A(c) and 2B]. These results suggest that the inhibition of
thrombin-induced human platelet aggregation by KRG-TS is greatly
dependent on cAMP-dependent Ca2þ-antagonistic condition than
cGMP-dependent Ca2þ-antagonistic condition.3.3. Effects of KRG-TS on [Ca2þ]i mobilization
We investigated the effect of KRG-TS on Ca2þ-antagonistic ac-
tivity. As shown in Fig. 3A, thrombin increased the [Ca2þ]i level
from 101.2  0.5nM (basal level) to 590.6  18.3nM (Fig. 3A, inset
table). However, this was signiﬁcantly decreased by various con-
centrations (25e150 mg/mL) of KRG-TS in a dose-dependent
manner (Fig. 3A). If the inhibition of [Ca2þ]i mobilization by KRG-
TS results from IP3R phosphorylation through the cAMP/PKA or
cGMP/PKG pathway, then the KRG-TS-reduced [Ca2þ]i level would
be increased by the PKA or PKG inhibitor. Accordingly, we investi-
gated the effects of PKA inhibitor (Rp-8-Br-cAMPS) and PKG in-
hibitor (Rp-8-Br-cGMPS) on KRG-TS-reduced [Ca2þ]i mobilization.
As shown in Fig. 3B, the PKA inhibitor Rp-8-Br-cAMPS (50e250mM)
dose dependently increased the [Ca2þ]i level compared with that
(110.9  1.9 nM) by KRG-TS (150 mg/mL) in the thrombin-induced
platelet aggregation. By contrast, the PKG inhibitor Rp-8-Br-phosphate-dependent protein kinase catalytic subunit (PKAc) phosphorylation. Lane 1,
TS (50 mg/mL); Lane 4, thrombin (0.05 U/mL) þ KRG-TS (100 mg/mL); Lane 5, thrombin
Rp-8-Br-cAMPS (250mM); and Lane 7, thrombin (0.05 U/mL) þ 8-(4-chlorophenylthio)-
as described in the “Materials and methods” section. Data are expressed as the
ts. **p < 0.05 versus the thrombin-stimulated human platelets in the presence of KRG-
Fig. 5. Effect of total saponin from Korean Red Ginseng (KRG-TS) on inositol 1,4,5-trisphosphate receptor type I (IP3RI) (Ser1756) phosphorylation. Lane 1, intact platelets (base); Lane
2, thrombin (0.05 U/mL); Lane 3, thrombin (0.05 U/mL) þ KRG-TS (100 mg/mL); Lane 4, thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL); Lane 5, thrombin (0.05 U/mL) þ KRG-TS
(150 mg/mL) þ Rp-8-Br-cAMPS (250mM); Lane 6, thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL) þ Rp-8-Br-cGMPS (250mM); Lane 7, thrombin (0.05 U/mL) þ 8-(4-chlorophenylthio)-
cyclic adenosine monophosphate (pCPT-cAMP; 1mM); and Lane 8, thrombin (0.05 U/mL) þ8-Br-cGMP (1mM). Western blotting was performed as described in the “Materials and
methods” section. Data are expressed as the mean  standard deviation (n ¼ 4). *p < 0.05 versus the thrombin-stimulated platelets, **p < 0.05 versus the thrombin-stimulated
human platelets in the presence of KRG-TS (150 mg/mL).
Table 2
Changes of p-IP3R to b-actin ratio
Ratio of p-IP3R
to b-actin
D (%)
Thrombin (0.05 U/mL) 2.7  0.1
KRG-TS (150 mg/mL) þ thrombin (0.05 U/mL) 267.6  7.3 þ9811.11)
KRG-TS (150 mg/mL) þ thrombin
(0.05 U/mL) þ Rp-8-Br-cAMPS (250mM)
148.9  2.1 44.32)
KRG-TS (150 mg/mL) þ thrombin
(0.05 U/mL) þ Rp-8-Br-cGMPS (250mM)
196.2  8.5 26.63)
Data are from Fig. 5
IP3R, inositol 1,4,5-trisphosphate receptor; KRG-TS, total saponin from Korean Red
Ginseng
1) D (%) ¼ [(KRG-TS þ thrombin)  thrombin]/thrombin  100
2) D (%)¼ [(KRG-TSþ thrombinþ Rp-8-Br-cAMPS) (KRG-TSþ thrombin)]/(KRG-
TS þ thrombin)  100
3) D (%)¼ [(KRG-TSþ thrombinþ Rp-8-Br-cGMPS) (KRG-TSþ thrombin)]/(KRG-
TS þ thrombin)  100
J Ginseng Res 2015;39:354e364360cGMPS (50e250mM) very weakly increased the [Ca2þ]i level
compared with that by KRG-TS (150 mg/mL; 110.9  1.9nM) in
thrombin-induced platelet aggregation (Fig. 3C). As shown in
Table 1, Rp-8-Br-cAMPS (250mM) increased the [Ca2þ]i level to
155.1% and Rp-8-Br-cGMPS (250mM) increased the [Ca2þ]i level to
29.4%, indicating that the reduction of [Ca2þ]i mobilization (Fig. 3A)
by KRG-TS may be more dependent on the pathway of cAMP/PKA
than cGMP/PKG. We, therefore, investigated the effect of KRG-TS on
phosphorylation of PKAc as an indicator of cAMP/PKA activation.
3.4. Effects of KRG-TS on PKAc (Thr197) phosphorylation
It is well-known that the phosphorylation of PKAc (Thr197) is
necessary to produce biological functions through the cAMP/PKA
pathway [23]. As shown in Fig. 4, KRG-TS dose dependently phos-
phorylated Thr197 in PKAc (42 kDa), and abruptly increased the
ratio of phosphorylated PKAc (Thr197) to b-actin in thrombin-
induced platelet aggregation (Fig. 4, lanes 4 and 5). The PKA in-
hibitor Rp-8-Br-cAMPS strongly decreased KRG-TS-elevated phos-
phorylation of PKAc (Thr197; Fig. 4, lane 6), meaning that the
phosphorylation of PKAc (Thr197) by KRG-TS depends on the cAMP/
PKA pathway. This is also supported by the fact that the PKA acti-
vator 8-(4-chlorophenylthio)-cAMP (pCPT-cAMP) increased the
phosphorylation of PKAc (Thr197; Fig. 4, lane 7).
3.5. Effects of KRG-TS on IP3RI (Ser
1756) phosphorylation in the
presence of PKA and PKG inhibitors
We then investigated the IP3RI phosphorylation-associated
PKAc (Thr197) phosphorylation. The phosphorylation of IP3RI(Ser1756) and the ratio of phosphorylated IP3RI (p-IP3RI; Ser1756) to
b-actin were increased in the presence of the PKA activator pCPT-
cAMP (Fig. 5, lane 7) in thrombin-induced human platelet aggre-
gation, indicating that cAMP/PKA is involved in the phosphoryla-
tion of IP3RI (Ser1756). As shown in Fig. 5 (lanes 3 and 4), the
phosphorylation of IP3RI (Ser1756) and the ratio of p-IP3RI (Ser1756)
to b-actin were dose dependently increased in the presence of both
thrombin and KRG-TS. To investigate whether cAMP/PKAc (Thr197)
phosphorylation by KRG-TS (Fig. 4, lane 5) is involved in IP3RI
(Ser1756) phosphorylation (Fig. 5, lane 4), we used the PKA inhibitor
Rp-8-Br-cAMPS (Fig. 4, lane 6) that inhibited KRG-TS-induced PKAc
(Thr197) phosphorylation. As shown in Fig. 5 (lane 5), the PKA
Fig. 6. Effects of total saponin fromKorean RedGinseng (KRG-TS) on adenosine triphosphate (ATP) and serotonin release. (A) Effects of KRG-TS onATP release in thrombin-activated platelets. (B) Effects of KRG-TS onATP release in the presence of
cyclic adenosinemonophosphate-dependentproteinkinase (PKA)orcyclic guanosinemonophosphate-dependentproteinkinase (PKG) inhibitor. (C)Effects ofKRG-TSon serotonin release. (D)Effects ofKRG-TSon serotonin release in thepresence
of PKA or PKG inhibitor. Data are expressed as mean standard deviation (n¼ 4). *p< 0.05 versus the thrombin-stimulated human platelets. **p< 0.05 versus the thrombin-stimulated human platelets in the presence of KRG-TS (150 mg/mL).
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Table 3
Effects of protopanaxadiol on thrombin-induced human platelet aggregation
Treatment (mM) Aggregation (%) Treatment (mM) Aggregation (%)
Thrombin (0.05 U/mL) 86.7  1.5 e e
Ginsenoside Ra1 Ginsenoside Rd
50 83.3  1.2 50 85.0  3.0
10 83.0  1.7 100 84.0  1.7
200 83.0  1.0 200 86.3  1.5
300 86.7  1.5 300 84.3  4.0
Ginsenoside Rb1 Ginsenoside Rg3 (20R)
50 83.0  1.7 50 86.7  1.5
100 84.3  0.6 100 86.0  2.0
200 85.3  3.1 200 75.7  3.2
300 83.0  3.5 300 62.0  2.0
Ginsenoside Rb2 Ginsenoside Rg3 (20S)
50 86.7  1.5 50 79.7  2.1 *
100 84.7  0.6 100 39.7  2.1 **
200 86.3  2.1 200 9.7  2.1 **
300 84.7  0.6 300 3.7  1.5 **
Ginsenoside Rb3 Ginsenoside Rh2 (20R)
50 82.3  3.5 50 83.3  1.2
100 85.7  1.2 100 84.7  0.6
200 83.7  1.5 200 85.3  3.1
300 84.0  3.6 300 81.0  1.7
Ginsenoside Rc
50 84.7  3.2 e e
100 84.7  0.6 e e
200 86.3  2.1 e e
300 84.0  2.6 e e
Results are expressed as percentage of aggregation induced by thrombin. The data
are expressed as the mean  standard deviation (n ¼ 4)
*p < 0.05, **p < 0.01 versus the thrombin-stimulated human platelets
Table 4
Effects of protopanaxatriol on thrombin-induced human platelet aggregation
Treatment (mM) Aggregation (%) Treatment (mM) Aggregation (%)
Thrombin (0.05 U/mL) 86.7  1.5 e e
Ginsenoside Re Ginsenoside Rg2 (20R)
50 82.7  1.2 50 84.0  2.6
100 82.3  1.5 100 87.0  1.0
200 85.3  2.5 200 85.3  2.9
300 84.7  0.6 300 86.0  2.6
Ginsenoside Rf Ginsenoside Rh1 (20S)
50 82.7  2.1 50 84.3  1.5
100 86.7  1.5 100 83.3  2.1
200 84.7  0.6 200 82.7  1.2
300 83.0  1.0 300 85.3  2.5
Ginsenoside Rg1
50 84.3  2.1 e e
100 83.0  1.7 e e
200 84.7  4.0 e e
300 85.0  1.0 e e
Results are expressed as percentage of aggregation induced by thrombin. The data
are expressed as the mean  standard deviation (n ¼ 4)
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the ratio of p-IP3RI (Ser1756) to b-actin achieved by both thrombin
and KRG-TS. These results indicate that the increase of p-IP3RI
(Ser1756) by KRG-TS is dependent on cAMP/PKAc (Thr197). The PKG
inhibitor Rp-8-Br-cGMPS also decreased KRG-TS-induced p-IP3RI
(Ser1756; Fig. 5, lane 6). However, its inhibitory degree (22.6%) was
lower compared with that of the PKA inhibitor Rp-8-Br-cAMPS
(44.3%; Table 2), indicating that the increase of p-IP3RI (Ser1756) by
KRG-TS is effected through the cAMP/PKA pathway.
3.6. Effects of KRG-TS on ATP and serotonin release
Intracellular [Ca2þ]i mobilization is known to be involved in the
release of ATP and serotonin from a dense body of platelets [24].
Because KRG-TS inhibited thrombin-elevated [Ca2þ]i mobilization
(Fig. 3A), we investigated whether KRG-TS is involved in the inhi-
bition of ATP and serotonin release. As shown in Fig. 6, KRG-TS dose
dependently inhibited thrombin-induced ATP (Fig. 6A) and sero-
tonin release (Fig. 6C). Because the inhibition of [Ca2þ]i mobiliza-
tion by KRG-TS was dependent on cAMP/PKA and cGMP/PKG
pathways, we investigated whether the inhibition of ATP and se-
rotonin release by KRG-TS resulted from cAMP/PKA and cGMP/PKG
pathways. The PKA inhibitor Rp-8-Br-cAMPS (Fig. 6B) and the PKG
inhibitor Rp-8-Br-cGMPS (Fig. 6D) increased KRG-TS-decreased ATP
and serotonin release.
These results indicate that the inhibition of ATP and serotonin
release by KRG-TS (Figs. 6A and 6C) is dependent on the cAMP/PKA
and cGMP/PKG-pathways. The results are supported by the fact that
the PKA activator pCPT-cAMP (Fig. 6B) and the PKG activator 8-Br-
cGMP (Fig. 6D) inhibit thrombin-induced ATP and serotonin
release.
3.7. Effects of ginsenosides in KRG-TS on thrombin-induced platelet
aggregation
In a previous report [18], ﬁve ginsenosides (G-Rb1, G-Rb2, G-Rc,
G-Rd, and G-Rg3) were reported as 20(S)-PPDS and three ginse-
nosides (G-Re, G-Rg1, and G-Rg2) as 20(S)-PPTS. Besides these
ginsenosides, it is known that G-Ra1, G-Rb3, and G-Rh2 as PPDS and
G-Rf and G-Rh1 as PPTS are also present in P. ginseng [25]. There-
fore, to investigate which ginsenoside of KRG-TS was involved in
the inhibition of thrombin-induced human platelet aggregation, we
investigated the effect of ginsenosides in KRG-TS and other ginse-
nosides on thrombin-induced human platelet aggregation. In this
study, G-Ra1, G-Rb1, G-Rb2, G-Rb3, G-Rc, G-Rd, and G-Rh2(20R) of
PPDS did not inhibit thrombin-induced human platelet aggrega-
tion, but only G-Rg3 (20R, 20S) dose dependently inhibited
thrombin-induced human platelet aggregation (Table 3). In addi-
tion, none of the PPTSs [G-Re, G-Rf, G-Rg1, G-Rg2 (20R), and G-Rh1
(20S)] inhibited thrombin-induced human platelet aggregation
(Table 4).
4. Discussion
Although KRG-TS elevated cAMP only in thrombin-induced
human platelets [17], to conﬁrm whether the cAMP/PKA or
cGMP/PKG pathway contributed to the inhibition of platelet ag-
gregation by KRG-TS, we investigated the effect of PKA inhibitor
and PKG inhibitor on thrombin-induced human platelet aggrega-
tion in the presence of KRG-TS. The results showed that the PKA
inhibitor Rp-8-Br-cAMPS and the PKG inhibitor Rp-8-Br-cGMPS
increased KRG-TS-decreased light transmission in thrombin-
induced human platelet aggregation. However, the elevation of
light transmission by the PKA inhibitor was stronger than that by
the PKG inhibitor in KRG-TS-inhibited thrombin-induced humanplatelet aggregation. These results show that the cAMP/PKA
pathway mainly contributed to the inhibition of thrombin-induced
platelet aggregation and [Ca2þ]i mobilization by KRG-TS. Several
aggregation-inducing molecules (Ca2þ, TXA2, etc.) are commonly
generated by agonists such as thrombin, collagen, and adenosine
diphosphate (ADP). The IP3 mobilizes [Ca2þ]i, and subsequently
activates Ca2þ-dependent PLC or phospholipase-A2 to separate the
TXA2 precursor arachidonic acid (20:4) from glycerophospholipids,
and TXA2 is produced by activation of COX-1/TXAS. TXA2 produces
IP3 to mobilize [Ca2þ]i through the G-protein-coupled receptor/
PLC-b pathway, and constricts the blood vessel tract [5,26e28],
which enforces thrombus formation. Therefore, the inhibition of
[Ca2þ]i mobilization by IP3 and TXA2 production by COX-1/TXAS are
very important to evaluate the antiplatelet effect of a substance. A
previous report [17] conﬁrmed that KRG-TS inhibits TXA2
J.-H. Shin et al / Inhibition of [Ca2+]i mobilization 363production by attenuating COX-1 and TXAS activities. Although
KRG-TS inhibited thrombin-induced [Ca2þ]i mobilization, its
inhibitory mechanism is unknown. The Ca2þ-antagonistic reaction
by cAMP and cGMP is mediated by both PKA/IP3RI and PKG/IP3RI
phosphorylation pathways. Because KRG-TS elevated the level of
cAMP [18], if KRG-TS stimulates IP3RI (Ser1756) phosphorylation in
thrombin-activated human platelets, it is clear evidence that KRG-
TS inhibits [Ca2þ]i mobilization through the cAMP/PKA/IP3RI
(Ser1756) phosphorylation pathway. In this report, we conﬁrmed
that KRG-TS inhibited [Ca2þ]i mobilization through IP3RI (Ser1756)
phosphorylation by cAMP/PKAc, which is supported by the fact that
the cAMP inhibitor Rp-8-Br-cAMPS inhibited KRG-TS-elevated
phosphorylation of both IP3RI (Ser1756) and PKAc (Thr197) in
thrombin-induced human platelet aggregation, otherwise the
cAMP inhibitor Rp-8-Br-cAMPS would not increase KRG-TS-
decreased [Ca2þ]i mobilization in thrombin-induced human
platelet aggregation. It is known that IP3 induces serotonin release
from platelet-dense bodies, meaning that IP3 is involved in sero-
tonin release by elevating [Ca2þ]i through IP3RI [29]. This reﬂects
the fact that KRG-TS may be involved in the inhibition of serotonin
release by phosphorylating IP3RI (Ser1756).
A lot of agonists such as collagen, thrombin, and ADP mobilize
[Ca2þ]i to phosphorylate Ca2þ/calmodulin-dependent myosin light
chain (20 kDa), which plays a role in secretion of granules such as
serotonin and ATP [6,7], and platelet aggregation. It is thought that
the inhibition of ATP and serotonin secretion by KRG-TS results
from the elevation of Ca2þ-antagonistic molecule cAMP and sub-
sequent inhibition of [Ca2þ]i mobilization, which is also supported
by the fact that KRG-TS stimulated the phosphorylation of both
PKAc (Thr197) and IP3RI (Ser1756).
Platelet aggregation is generated at the site of vascular wall
injury, and is involved in the formation of thrombus. During the
formation of thrombus, platelets release cell growth proteins [e.g.,
platelet-derived growth factor (PDGF)] and vascular endothelial
growth factor (VEGF) in a-granules [30,31]. It is well-established
that PDGF and VEGF induce the proliferation of ﬁbroblast,
vascular smooth cells, and epithelial cells, and subsequently
enhance the rate of atherosclerosis lesion progression [32e36]. The
progression of atherosclerosis is strongly induced by inﬂammatory
cells such as monocytes/macrophages and neutrophils [37].
Although KRG-TS shows antiplatelet effects, if KRG-TS does not
inhibit inﬂammation by leukocytes, progression of atherosclerosis
lesion occurs at the site of vascular wall injury, which raises
questions about the antiplatelet effects of KRG-TS. Byeon et al [38]
reported that saponin fraction inhibits lipopolysaccharide (LPS)-
induced inﬂammation, and it is well-known that ginsenosides
exhibit anti-inﬂammatory effects by inhibiting the production of
various proinﬂammatory mediators such as prostaglandin E2 and
NO [39]. Recently, it was reported that saponin fractions of KRG
downregulate LPS-induced proinﬂammatory mediators (i.e., NO
and interleukin-1b) [40]. Considering these three previous reports
[38e40], it is thought that KRG-TS may exhibit antithrombotic and
antiatherosclerotic effects without causing inﬂammation and pro-
gression of atherosclerotic lesion at the site of vascular wall injury.
Therefore, KRG-TS is highlighted as a “nontoxic antiplatelet com-
pound,” and could be clinically applied to the prevention of
platelet-mediated thrombosis. This result is supported by a previ-
ous study suggesting the protective effects of KRG on carotid artery
thrombosis in vivo in rats [41]. In addition, both ginseng and gin-
senosides are very useful for prevention of cardiovascular disease
[42].
With regard to the antiplatelet effects of ginsenosides in KRG-TS,
only G-Rg3 (20R, 20S) inhibited thrombin-induced platelet aggre-
gation. This is in accordance with the reports that G-Rg3 (20R, 20S)
inhibited arachidonic acid- or U46619-induced platelet aggregation[43], and its analog (G-Rp1, dihydroxy G-Rg3) inhibited collagen- or
thrombin-induced platelet aggregation [19,20]. Other reports also
suggested that G-Rg1 [molecular weight (MW) ¼ 800.94] and G-
Rg2 (MW ¼ 781.01) inhibit various agonists (i.e., thrombin,
collagen, ADP)-induced platelet aggregation [44e46], but the
inhibitory concentrations were 1 mg/mL (1.2mM) to 4 mg/mL
(5mM) for G-Rg1 [44,45] and 1 mg/mL (1.3mM) for G-Rg2 [45,46].
These inhibitory concentrations (1.2e5mM) of G-Rg1 or G-Rg2
(1.3mM) [44e46] are very high compared with those of G-Rg3 and
its analogues (G-Rp1, dihydroxy G-Rg3), which exhibited anti-
platelet effect at concentrations in the range of micromoles
[19,20,43]. Therefore, it is thought that the antiplatelet effects
exhibited by G-Rg1 and G-Rg2 should be re-evaluated. Because
only G-Rg3 in KRG-TS inhibited thrombin-induced human platelet
aggregation, it is thought that G-Rg3 in KRG-TS might have
contributed to the inhibition of platelet aggregation and [Ca2þ]i
mobilization, which also supports the report that G-Rg3 elevated
Ca2þ-antagonistic cAMP levels [20].
Thrombosis mainly results from the irreversible aggregation,
which is closely related to the serotonin released from platelets
activated by agonists (i.e., collagen and thrombin) [47e49]. In
addition, the released serotonin is involved in causing migraine
[50e52].
In conclusion, the most important result of this study is that
KRG-TS signiﬁcantly phosphorylates IP3RI (Ser1756) to inhibit
thrombin-induced [Ca2þ]i mobilization, which contributed to
attenuating the release of ATP and serotonin. Therefore, our results
suggest that KRG-TS may be a physiologically effective negative
regulator in platelet aggregation, a cause of thrombosis, athero-
sclerosis, and myocardial infarction. Because KRG-TS also inhibits
serotonin release, it should also be evaluated as an antimigraine
substance.
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